PF-Atlas › Clinical Trials › NCT01044719

Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis

Ceftazidime · Phase 4

Registry ID

NCT01044719

Phase

Phase 4

Status

Unknown

Drug / intervention

Ceftazidime

Sponsor

Imperial College London

Start

2010-01

Enrollment

240

Locations

About this trial

Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.

View NCT01044719 on ClinicalTrials.gov →

Explore related

All Ceftazidime trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01044719 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.